Phibro Animal Health Corporation · NASDAQ:PAHC
Phibro Animal Health — Q1 FY2018 Earnings Presentation
12 slides from Phibro Animal Health's earnings presentation, Nov 7, 2017
Slide 1: Phibro Animal Health Corporation First Quarter - September 2017
Phibro Animal Health Corporation First Quarter - September 2017 U.S. toll-free +1-877-853-5634 Webcast and Conference Call International toll +1-315-625-6893 November 7, 2017 Conference ID: 93299558
Slide 2: Cautionary Statements
Cautionary Statements Forward-Looking Statements This communication contains forward-looking statements that are subject to risks and uncertainties. All statements other than statements of historical or current fact included in this report are forward-looking statements. Forward-looking statements d
Slide 3: Opening Remarks and Financial Review
Opening Remarks and Financial Review Jack Bendheim Chairman, President, Chief Executive Officer Richard Johnson Chief Financial Officer Webcast and Conference Call November 7, 2017 3
Slide 4: GAAP and Non-GAAP Financial Information
GAAP and Non-GAAP Financial Information Reported results are presented in accordance with GAAP Adjusted results are GAAP results adjusted to exclude: - Acquisition-related items, including intangible amortization, cost of goods sold, accrued compensation costs, transaction costs and accrued interest
Slide 5: Highlights
Highlights Q1 – September 2017 For the three months ended September 30 2017 2016 Change Net income and diluted EPS improved due to: (in millions, except per share amounts and percentages) Reduced acquisition-related transaction costs Net sales $ 193.4 $ 188.0 $ 5.4 3% Lower interest expense, net fro
Slide 6: Selected Line Items
Selected Line Items Q1 – September 2017 For the three months ended September 30 2017 2016 Change Adjusted SG&A increased due to Animal Health (in millions, except per share amounts and percentages) sales force expansion and product development Net sales $ 193.4 $ 188.0 $ 5.4 3% costs to position our
Slide 7: Animal Health
Animal Health Q1 – September 2017 Sales For the three months ended September 30 2017 2016 Change - Nutritional specialties: Volume growth in U.S. poultry (in millions, except percentages) and dairy industries - Vaccines: volume growth in the poultry and swine MFAs and other $ 79.6 $ 83.4 $ (3.8) (5)
Slide 8: Other Segments
Other Segments Q1 – September 2017 For the three months ended 2017 2016 Change September 30 (in millions, except percentages) Mineral Nutrition Mineral Nutrition Net sales $ 52.1 $ 51.6 $ 0.5 1% – Sales growth on increased commodity pricing, partially offset by lower volumes Adjusted EBITDA $ 3.7 $
Slide 9: Capitalization and Capital Allocation
Capitalization and Capital Allocation September 30, 2017 2.8x leverage ratio at September 30, 2017 - $334 million total debt - $120 million LTM adjusted EBITDA $62 million cash on hand at September 30, 2017 Net cash flow before business acquisitions and financing was approximately break-even in the
Slide 10: Guidance
Guidance For the year ending June 30 2018 2017 Change (in millions, except per share amounts and percentages) Net sales - Animal Health segment $ 500.0 - $ 515.0 $ 497.7 $ 2.3 - $ 17.3 0% - 3% Net sales 765.0 - 790.0 764.3 0.7 - 25.7 0% - 3% Net income per share - diluted $ 1.43 - $ 1.56 $ 1.61 $ (0
Slide 11: Q & A Session
Q&A Session Webcast and Conference Call November 7, 2017 11
Slide 12: © 2017 Phibro Animal Health Corporation, Teaneck, NJ 07666 Phibro; Healthy Animals. Healthy Food.
© 2017 Phibro Animal Health Corporation, Teaneck, NJ 07666 Phibro; Healthy Animals. Healthy Food. Healthy World.; AB20; Animate; Aviax; Bloat Guard; Cellerate Yeast Solutions; Gemstone; Lactrol; Magni-Phi; Mecadox; MJPRRS; Neo-Terra; TM; Nicarb; OmniGen-AF; PAQ-Gro; Stafac; TAbic; Terramycin; V-Max;
Phibro Animal Health — Q1 FY2018 Earnings Presentation on 6ix